Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes

H. Olbertova, K. Plevova, S. Pavlova, J. Malcikova, J. Kotaskova, K. Stranska, M. Spunarova, M. Trbusek, V. Navrkalova, B. Dvorackova, N. Tom, K. Pal, M. Jarosova, Y. Brychtova, A. Panovska, M. Doubek, S. Pospisilova

. 2022 ; 22 (1) : 137. [pub] 20220203

Language English Country Great Britain

Document type Journal Article

Grant support
MH-CZ RVO 65269705 Ministerstvo Zdravotnictví Ceské Republiky
AZV NU21-08-00237 Ministerstvo Zdravotnictví Ceské Republiky
AZV NV19-03-00091 Ministerstvo Zdravotnictví Ceské Republiky
GACR 19-15737S Grantová Agentura České Republiky
GACR 19-11299S Grantová Agentura České Republiky
LM2018132 Technologická Agentura České Republiky
LM2018133 Technologická Agentura České Republiky
CZ.02.1.01/0.0/0.0/18_046/0015515 Ministerstvo Školství, Mládeže a Tělovýchovy

BACKGROUND: Telomeres are protective structures at chromosome ends which shorten gradually with increasing age. In chronic lymphocytic leukemia (CLL), short telomeres have been associated with unfavorable disease outcome, but the link between clonal evolution and telomere shortening remains unresolved. METHODS: We investigated relative telomere length (RTL) in a well-characterized cohort of 198 CLL patients by qPCR and focused in detail on a subgroup 26 patients who underwent clonal evolution of TP53 mutations (evolTP53). In the evolTP53 subgroup we explored factors influencing clonal evolution and corresponding changes in telomere length through measurements of telomerase expression, lymphocyte doubling time, and BCR signaling activity. RESULTS: At baseline, RTL of the evolTP53 patients was scattered across the entire RTL spectrum observed in our CLL cohort. RTL changed in the follow-up samples of 16/26 (62%) evolTP53 cases, inclining to reach intermediate RTL values, i.e., longer telomeres shortened compared to baseline while shorter ones prolonged. For the first time we show that TP53 clonal shifts are linked to RTL change, including unexpected RTL prolongation. We further investigated parameters associated with RTL changes. Unstable telomeres were significantly more frequent among younger patients (P = 0.032). Shorter telomeres were associated with decreased activity of the B-cell receptor signaling components p-ERK1/2, p-ZAP-70/SYK, and p-NFκB (P = 0.04, P = 0.01, and P = 0.02, respectively). CONCLUSIONS: Our study revealed that changes of telomere length reflect evolution in leukemic subclone proportion, and are associated with specific clinico-biological features of the explored cohort.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011067
003      
CZ-PrNML
005      
20220506130417.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-022-09221-z $2 doi
035    __
$a (PubMed)35114947
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Olbertova, Helena $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes / $c H. Olbertova, K. Plevova, S. Pavlova, J. Malcikova, J. Kotaskova, K. Stranska, M. Spunarova, M. Trbusek, V. Navrkalova, B. Dvorackova, N. Tom, K. Pal, M. Jarosova, Y. Brychtova, A. Panovska, M. Doubek, S. Pospisilova
520    9_
$a BACKGROUND: Telomeres are protective structures at chromosome ends which shorten gradually with increasing age. In chronic lymphocytic leukemia (CLL), short telomeres have been associated with unfavorable disease outcome, but the link between clonal evolution and telomere shortening remains unresolved. METHODS: We investigated relative telomere length (RTL) in a well-characterized cohort of 198 CLL patients by qPCR and focused in detail on a subgroup 26 patients who underwent clonal evolution of TP53 mutations (evolTP53). In the evolTP53 subgroup we explored factors influencing clonal evolution and corresponding changes in telomere length through measurements of telomerase expression, lymphocyte doubling time, and BCR signaling activity. RESULTS: At baseline, RTL of the evolTP53 patients was scattered across the entire RTL spectrum observed in our CLL cohort. RTL changed in the follow-up samples of 16/26 (62%) evolTP53 cases, inclining to reach intermediate RTL values, i.e., longer telomeres shortened compared to baseline while shorter ones prolonged. For the first time we show that TP53 clonal shifts are linked to RTL change, including unexpected RTL prolongation. We further investigated parameters associated with RTL changes. Unstable telomeres were significantly more frequent among younger patients (P = 0.032). Shorter telomeres were associated with decreased activity of the B-cell receptor signaling components p-ERK1/2, p-ZAP-70/SYK, and p-NFκB (P = 0.04, P = 0.01, and P = 0.02, respectively). CONCLUSIONS: Our study revealed that changes of telomere length reflect evolution in leukemic subclone proportion, and are associated with specific clinico-biological features of the explored cohort.
650    _2
$a klonální evoluce $x genetika $7 D060965
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x genetika $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a protoonkogenní proteiny c-bcr $x metabolismus $7 D051562
650    _2
$a signální transdukce $7 D015398
650    _2
$a telomerasa $x genetika $7 D019098
650    _2
$a telomery $x ultrastruktura $7 D016615
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
700    1_
$a Plevova, Karla $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Pavlova, Sarka $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Malcikova, Jitka $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kotaskova, Jana $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Stranska, Kamila $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Spunarova, Michaela $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Trbusek, Martin $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Navrkalova, Veronika $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Dvorackova, Barbara $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Tom, Nikola $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic
700    1_
$a Pal, Karol $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic
700    1_
$a Jarosova, Marie $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Brychtova, Yvona $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Panovska, Anna $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Doubek, Michael $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Pospisilova, Sarka $u Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz $u Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz $1 https://orcid.org/0000000171362680
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 22, č. 1 (2022), s. 137
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35114947 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130409 $b ABA008
999    __
$a ok $b bmc $g 1788921 $s 1162265
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 22 $c 1 $d 137 $e 20220203 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
GRA    __
$a MH-CZ RVO 65269705 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a AZV NU21-08-00237 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a AZV NV19-03-00091 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a GACR 19-15737S $p Grantová Agentura České Republiky
GRA    __
$a GACR 19-11299S $p Grantová Agentura České Republiky
GRA    __
$a LM2018132 $p Technologická Agentura České Republiky
GRA    __
$a LM2018133 $p Technologická Agentura České Republiky
GRA    __
$a CZ.02.1.01/0.0/0.0/18_046/0015515 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...